M&A Deal Summary

H. Lundbeck Acquires Alder Biopharmaceuticals

On September 16, 2019, H. Lundbeck acquired life science company Alder Biopharmaceuticals for 2.0B USD

Acquisition Highlights
  • This is H. Lundbeck’s 5th transaction in the Life Science sector.
  • This is H. Lundbeck’s 2nd largest (disclosed) transaction.
  • This is H. Lundbeck’s 4th transaction in the United States.
  • This is H. Lundbeck’s 1st transaction in Washington.

M&A Deal Summary
Date 2019-09-16
Target Alder Biopharmaceuticals
Sector Life Science
Buyer(s) H. Lundbeck
Deal Type Add-on Acquisition
Deal Value 2.0B USD
Advisor(s) Centerview Partners (Financial)
Skadden, Arps, Slate, Meagher & Flom
Cooley (Legal)

Target

Alder Biopharmaceuticals

Bothell, Washington, United States
Alder Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel antibodies that originate from its proprietary platform for the production of antibodies in picchia. Alder Biopharmaceuticals was formed in 2002 and is based in Bothell, Washington.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

H. Lundbeck

Valby, Denmark
Category Company
Founded 1915
Sector Healthcare Services
Employees5,681
Revenue 19.9B DKK (2023)
DESCRIPTION

H. Lundbeck A/S is an international pharmaceutical company engaged inthe research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. H. Lundbeck was founded in 1915 and is based in Valby, Denmark.

DEAL STATS #
Overall 5 of 6
Sector (Life Science) 5 of 6
Type (Add-on Acquisition) 4 of 5
State (Washington) 1 of 1
Country (United States) 4 of 5
Year (2019) 2 of 2
Size (of disclosed) 2 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-05-06 Abide Therapeutics

San Diego, California, United States

Abide Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to realizing the therapeutic value of first-in-class endocannabinoid modulators to transform the lives of patients with serious unmet medical needs. Abide Therapeutics, Inc. was founded in 2011 and is based in San Diego, California.

Buy $250M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-10-14 Longboard Pharmaceuticals

La Jolla, California, United States

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals was founded in 2020 and is based in La Jolla, California.

Buy $2.6B
Mergr

Product

Company

Legal